European journal of endocrinology · 2026
Prevalence of germline variants in USP8, USP48, CABLES1 and PAM in patients with pituitary adenomas.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martinez de Lapiscina Idoia, Baquero Candela, Santos Alicia, Molina Ana Rosa, Moure Maria Dolores, Aramburu Maite, Bancalari Rodrigo, Boronat Mauro, Bueno Gloria, Casano-Sancho Paula, Fernandez-Ramos Concepcion, Garcia-Garcia Emilio, Gonzalez Amparo, Gonzalez-Rivera Natividad, Guerrero-Fernandez Julio, Hernandez Maria Isabel, Paja Miguel, Portillo Nancy, Rica Itxaso, Soto-Moreno Alfonso, Suarez-Ortega Larisa, Vela Amaia, Castaño Luis, Valdes Nuria, Hispanic-Chilean Pituitary Adenomas Collaborative Group
Аннотация
OBJECTIVE: Approximately 5% of pituitary adenomas (PA) are familial, linked to germline variants in AIP, or syndrome-related genes like MEN1. While somatic GNAS and USP8 variants predominate in specific subtypes, PAM and CABLES1 genes are emerging.
DESIGN: To investigate the prevalence and clinical significance of germline variants in CABLES1, USP8, USP48, and PAM in patients with PA without established predisposition gene variants.
METHODS: We analyzed germline DNA from 346 unrelated patients (mostly diagnosed <35 years) with isolated familial or sporadic PA, using a panel targeting CABLES1, USP8, USP48, and PAM. After excluding 20 with variants in known predisposition genes (MEN1, AIP, CDKN1B, PRKAR1A, SDHB, SDHC, SDHD, GNAS, DICER1), 326 patients remained for analysis. Variant interpretation followed American College of Medical Genetics and Genomics criteria with population frequencies, in silico prediction and segregation analysis. We analyzed tumor DNA from 2 cases to assess loss of heterozygosity (LOH).
RESULTS: Uncommon heterozygous germline variants were identified in 30 patients (9.2%), all clinically sporadic. Most variants were classified as benign or of uncertain significance (VUS). Several variants, including USP8 c.104+3A>G, USP48 p.(Pro361Thr), p.(Tyr927Cys) and c.2884 3C>T, and CABLES1 p.(Glu178Lys), were enriched compared with gnomAD frequencies. CABLES1 variants were predominant in macroprolactinomas, USP48 in nonfunctioning PA, and USP8 in prolactinomas and somatotropinomas. No significant genotype-phenotype associations emerged. Familial testing revealed unaffected carriers and LOH was not detected.
CONCLUSIONS: No (likely) pathogenic germline variants were identified. While most were benign or VUS, specific variants-most notably in USP48-showed nominal enrichment compared to gnomAD frequencies, which might suggest a potential low-penetrance susceptibility or modifier effect that will require further validation. This work primarily focused on PAM, CABLES1, USP8, and USP48, but other germline or somatic variants may also contribute. Clinical management and genetic counseling should not be guided by benign variants or VUS.
DESIGN: To investigate the prevalence and clinical significance of germline variants in CABLES1, USP8, USP48, and PAM in patients with PA without established predisposition gene variants.
METHODS: We analyzed germline DNA from 346 unrelated patients (mostly diagnosed <35 years) with isolated familial or sporadic PA, using a panel targeting CABLES1, USP8, USP48, and PAM. After excluding 20 with variants in known predisposition genes (MEN1, AIP, CDKN1B, PRKAR1A, SDHB, SDHC, SDHD, GNAS, DICER1), 326 patients remained for analysis. Variant interpretation followed American College of Medical Genetics and Genomics criteria with population frequencies, in silico prediction and segregation analysis. We analyzed tumor DNA from 2 cases to assess loss of heterozygosity (LOH).
RESULTS: Uncommon heterozygous germline variants were identified in 30 patients (9.2%), all clinically sporadic. Most variants were classified as benign or of uncertain significance (VUS). Several variants, including USP8 c.104+3A>G, USP48 p.(Pro361Thr), p.(Tyr927Cys) and c.2884 3C>T, and CABLES1 p.(Glu178Lys), were enriched compared with gnomAD frequencies. CABLES1 variants were predominant in macroprolactinomas, USP48 in nonfunctioning PA, and USP8 in prolactinomas and somatotropinomas. No significant genotype-phenotype associations emerged. Familial testing revealed unaffected carriers and LOH was not detected.
CONCLUSIONS: No (likely) pathogenic germline variants were identified. While most were benign or VUS, specific variants-most notably in USP48-showed nominal enrichment compared to gnomAD frequencies, which might suggest a potential low-penetrance susceptibility or modifier effect that will require further validation. This work primarily focused on PAM, CABLES1, USP8, and USP48, but other germline or somatic variants may also contribute. Clinical management and genetic counseling should not be guided by benign variants or VUS.